BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25476425)

  • 21. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
    Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
    [No Abstract]   [Full Text] [Related]  

  • 22. [Outcome of children and adolescents with Burkitt lymphoma and diffuse large B cell lymphoma treated with a modified NHL-BFM-90 protocol].
    Sun XF; Zhen ZJ; Xia Y; Lin SX; Zhu J; Wang J; Lu SY; Sun FF; Chen Y; Zhang F; Cai RQ; Li PF
    Zhonghua Xue Ye Xue Za Zhi; 2013 Dec; 34(12):1032-7. PubMed ID: 24369160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
    Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
    Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
    Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A
    Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
    Ahmad N; Zaidi A; Badar F; Maaz AU; Akram MS
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):49-56. PubMed ID: 20398038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcome of AT-B88 regimen for B-cell non-Hodgkin's lymphoma and surface immunoglobulin-positive acute lymphoblastic leukemia in children.
    Horibe K; Akiyama Y; Kobayashi M; Ishii E; Matsuyama T; Matsuzaki A; Minegishi M; Ueda K
    Int J Hematol; 1997 Jul; 66(1):89-98. PubMed ID: 9220664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
    Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
    J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.
    Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK
    Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Head and neck presentations of B-NHL and B-AL in children/adolescents: experience of the LMB89 study.
    Lervat C; Auperin A; Patte C; Méchinaud F; Leverger G; Nelken B; Bertrand Y; Baruchel A; Coze C; Munzer M; Lacombe MJ; Bergeron C
    Pediatr Blood Cancer; 2014 Mar; 61(3):473-8. PubMed ID: 23970385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report.
    Lones MA; Perkins SL; Sposto R; Tedeschi N; Kadin ME; Kjeldsberg CR; Wilson JF; Zwick DL; Cairo MS
    J Clin Oncol; 2002 May; 20(9):2293-301. PubMed ID: 11981000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
    Kamieńska E
    Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
    Burkhardt B; Woessmann W; Zimmermann M; Kontny U; Vormoor J; Doerffel W; Mann G; Henze G; Niggli F; Ludwig WD; Janssen D; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2006 Jan; 24(3):491-9. PubMed ID: 16421426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
    Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
    N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.
    Worch J; Rohde M; Burkhardt B
    Pediatr Hematol Oncol; 2013 Sep; 30(6):465-83. PubMed ID: 23570584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
    Mora J; Filippa DA; Qin J; Wollner N
    Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of children and adolescents with non-Hodgkin's lymphoma (results based on the NHL Berlin-Frankfurt-Münster 90 protocols).
    Kavan P; Kabicková E; Gajdos P; Koutecký J; Smelhaus V; Stanková J; McClain KL
    Cas Lek Cesk; 1999 Jan; 138(2):40-6. PubMed ID: 10376402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
    Meinhardt A; Burkhardt B; Zimmermann M; Borkhardt A; Kontny U; Klingebiel T; Berthold F; Janka-Schaub G; Klein C; Kabickova E; Klapper W; Attarbaschi A; Schrappe M; Reiter A;
    J Clin Oncol; 2010 Jul; 28(19):3115-21. PubMed ID: 20516455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.